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Abstract Pulmonaryarterialhypertensionis amalignantdiseasewith amedian survival of 3 years.Uric acid levels are
elevated in severe heart failure and in states of hypoxemia.Early data suggest a correlation between hyperuricemia and
severe pulmonary arterial hypertension.We studied 29 patients with pulmonary arterial hypertension diagnosed and
treated between1998 and 2001.Clinical characteristics (6 minwalk test and NewYork Heart Association class) and he-
modynamicparameters (pulmonaryarterypressure, pulmonary vascularresistance andcardiacoutput) were evaluated
and correlated to uric acid level in a retrospective study.Uric acid levels correlated positively with NewYork Heart As-
sociation class (r¼0.66, Po0.001) and negatively with 6minwalk test (r¼0.35, P¼0.03).Uric acid levels were higher in
patientswho died than in patientswho survived atthe end of the follow-up period (8.8 vs.5.7mg/dl, P¼0.001).This study
showsthaturic acidlevels are elevatedin severepulmonaryarterialhypertension andcanbeusedas aprognosticmarker
of disease severity. r2002 Elsevier Science Ltd.Allrights reserved.
Available online athttp://www.sciencedirect.com
Keywords uric acid, pulmonary arterial hypertension, prognostic marker.INTRODUCTION
Serum uric acid, the ¢nal product of purine degradation,
is elevated in states of urate overproduction (myelo- and
lymphoproliferative diseases), decreased uric acid excre-
tion (renal insu⁄ciency) or as a part of a metabolic syn-
drome (insulin resistance) (1). Hyperuricemia is reported
tohave a strongindependantcorrelationwith the severity
of symptoms andmortality of patients with heart failure
(2). It has also been shown to be released from ischemic
heart tissue during anginal syndrome (3). Two previously
published studies have suggested thaturic acid level is ele-
vated in primary pulmonary arterial hypertension (PPH)
andmaypredictmortality (4,5).The aim of this study is to
evaluate the correlation between serum uric acid level
and the severity of PPH, and to investigate the use of uric
acid level as a prognostic marker in these patients.
METHODS
Patient selection
We studied consecutive patients treated for pulmonary
arterial hypertension (meanpulmonary arterial pressureReceived17 June 2002, accepted in revised form 27 August 2002
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Tikva 49100, Israel.Fax: +972-3-9242091; E-mail: pulm@netvision.net.il425mmHg with normal pulmonary capillary wedge
pressure) at the Rabin Medical Center and the Ramban
Hospital between 1998 and 2001. Other causes of pul-
monary hypertension were excluded by lung perfusion
scanning, spiral CTand pulmonary function test. Patient
evaluation included a clinical pro¢le comprised of New
York Heart Association (NYHA) class, 6min walk test
and oxygen saturation; and a hemodynamic pro¢le com-
prised of pulmonary arterial pressure, pulmonary vascu-
lar resistance and cardiac output (measured by Fick’s
method) at right heart catheterization. Patients who
did not undergo catheterizationwere diagnosed and fol-
lowed up by means of transthoracic echocardiography.
Blood was tested for glucose, uric acid and kidney func-
tion at the start of follow-up. Uric acid was considered
elevated if the baseline level was greater than 6mg/dl
for women or 7mg/dl formen.
All the patients were treated with anticoagulants and
diuretics. Seventeen patients were treated with
prostacycline (10 subcutaneous, six intravenous, one in-
halation), and 12 patients were treated with calcium
blockers.
Stastitical analysis
Associations between dependent and independent
variables were computed using Kendall’s tau-b correla-
tion coe⁄cient. Kendall’s tau-b, which measures the
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ited by the constraints of normality required for Pear-
son’s correlation coe⁄cient, and thus may be used for
non-parametric quantitative and ordered category data.
It is the preferred correlation coe⁄cient for small data
sets with tied ranks, and may provide a better estimate
of correlation in the population than other coe⁄cients.
Student’s t-test for independentmeans was used to com-
pare uric acid levels across categories of the dichoto-
mous variables sex and survival. Analyses were
performedusing SPSSr forWindows (SPSS Inc.Chicago,
IL). All reported p-values are two-tailed, and values of
less than 0.05 were considered statistically signi¢cant.
RESULTS
Twenty-nine patients (25 females, four males) were en-
rolled in the study. Table1shows the clinical andhemody-
namic characteristics of the patients.Mean age was 54.9
(range from 16 to 80). After 3 years of follow-up there
were eight deaths (27.5%).Themean 6minwalk distanceTABLE 1. Patientcharacteristics
No. Age, sex PAP Syst
(mmHg)
CO
(L/mn)
NYHA
class
1. 26,F 72 2.8 II
2. 61,F 70 2.3 II
3. 34,F 38 7.6 II
4. 47,F 52 5.4 II
5. 43,F 42 4.0 II
6. 53,F 92 3.0 II
7. 65,M 90 2.5 II
8. 16,F 50 2.7 II
9. 67,F 85 F II
10. 67,M 85 F II
11. 65,M 55 4.2 III
12. 25,M 63 3.0 III
13. 72F 56 3.9 III
14. 52,F 52 6.3 III
15. 68,F 59 2.5 III
16. 55F 120 2.2 III
17. 56,F 100 4.5 III
18. 56,F 110 3.8 III
19. 53,F 85 3.0 III
20. 80,F 85 F III
21. 69,F 58 F III
22. 65,F 90 F III
23. 68,F 45 F III
24. 45,F 75 F III
25. 52,F 100 2.0 III
26. 54,F 45 2.7 III
27. 56,F 90 F III
28. 49,F 110 2.1 IV
29. 75,F 75 F IVwas 3417126m. Two patients were NYHA class IV, 17
were NYHA class III, and the remainder NYHA class II.
Six patients had resting oxygen saturation less than
90%.Themean systolic pulmonary arterial pressurewas
74723mmHg, and the mean cardiac output was
3.671.5 l/min. Sixteen patients (55%: 13 females, three
males) were hyperuricemic, while kidney function and
glucose levels were normal in all patients.
Uric acid correlation (Table 2)
Uric acidwas signi¢cantly higher in non-survivors than in
survivors (8.8 vs. 5.7mg/dl, P¼0.001) (Fig. 1). Serum uric
acid level showed a strong positive correlation with the
NYHA functional class (r¼0.66,Po0.001), indicating that
a higher uric acid value was associated with a worse
NYHAclass (Fig. 2). Serumuric acid level showed a nega-
tive correlation with the 6min walk test (r¼0.35,
P¼0.03), indicating that a higher uric acid valuewas asso-
ciated with poorer exercice capacity. Serum uric acid
was not signi¢cantly correlated with mean pulmonary6min
(m)
O2 Sat
(%)
Uric acid
(mg/dl)
Follow-up
(monthsFalive/dead)
370 98 2.9 36
572 95 2.7 24
473 98 2.8 36
292 90 4.2 36
426 98 4.0 24
450 94 6.1 36
360 90 5.7 36
F 96 5.3 18
459 94 3.0 30
423 90 6.0 18
400 98 7.0 24
439 97 7.0 24
262 94 9.4 36
219 91 8.5 12
330 88 4.0 36
120 95 4.3 6
100 85 7.0 12
324 92 8.6 36
333 95 8.9 6
430 96 7.9 24
430 96 7.9 36
250 97 7.7 36
420 92 6.3 36
F 92 9.4 6
F 91 7.1 36
F 89 8.7 24
F 98 7 6
100 90 14.2 6
F 94 10.5 24
FIG 1. Correlation between uric acid level and the mortality
rate: the uric acid levels were higher in patients who died than
inpatientswho survived (P¼0.001).
FIG 2. Correlation betweenthe NYHAclass and the uric acid
level.
TABLE 2. Correlation coe⁄cients for serum uric acid
and study variables
Variable Correlation coe⁄cient P value
Age 0.11 0.41
NYHA 0.66 0.001*
Oxygen saturation 0.18 0.20
Six-min. walk test 0.35 0.03*
PAP 0.19 0.17
CO 0.06 0.72
Survival 0.66 0.001*
*Correlation signi¢cant at 0.05 level.
132 RESPIRATORYMEDICINEarterial pressure, cardiac output, oxygen saturation
or age.
There was no correlation with the systemic arterial
hypertension, nor with the pulmonary vascular resis-
tance.
DISCUSSION
Pulmonary arterial hypertension is a severe progressive
disease characterized by vasoconstriction, vessel wall
remodelling and platelet aggregation. Elevated pulmon-
ary vascular resistance and low cardiac output are
strongly correlated to mortality, so that monitoring of
pulmonary arterial pressure requires repeated invasive
procedures such as right heart catheterization for asses-
sing the bene¢t of the treatment or the need for trans-
plantation (6,7).The ¢ndings of non-invasive procedures
are of clinical importance for patient follow-up, and have
been studied intensively during the last years.Miyamoto
etal. found thatpatientswhowalked less than 332mdur-ing 6min had a signi¢cantly lower survival than those
whowalked farther (8). Plasma brain natriuretic peptide
levels and urinary cGMP concentration have been also
found to be elevated in severe pulmonary arterial pres-
sure and to correlate closely withhemodynamic andclin-
ical parameters (9,10).
Nagaya demonstrated that hyperuricemia is common
in severe pulmonary hypertension, positively correlates
with pulmonary resistance, decreases during vasodilator
therapy in associationwith a reduction of pulmonary re-
sistance and positively correlated with mortality. Our
study also demonstrates a strong correlation between
elevated uric acid level, the NYHA class and mortality
of patients with pulmonary arterial pressure. Of the
eight patients with hyperuricemia, six died; all patients
in NYHA class IV were hyperuricemic.
The possible explanation of hyperuricemia in severe
pulmonary hypertension is that tissue hypoxia provokes
urate overproduction.Tissue ischemia depletes ATP and
stimulates the expression of the xanthine oxydase en-
zyme that elevates the xanthine, hypoxanthine and uric
acid levels (11). In fact, uric acid has been found to be
elevated in patients with severe COPD or in severe
OSA and corrected after oxygen delivery or non-inva-
sive ventilation treatment (12,13). However, in our study,
we didnot ¢nd a signi¢cantcorrelationbetween theoxy-
gen saturation anduric acid level andwe suggest that this
correlation is perhaps at the tissue level.
Despite the fact that low CO correlates positively
with the mortality (14), our study did not show a
HYPERURICEMIAINPULMONARYARTERIALHYPERTENSION 133statistical correlation betweenmortality and CO or be-
tween uric acid and CO.
All the patients received diuretics. It is well known
that thiazide and loop diuretics cause elevation of serum
uric acidby increasing its tubular reabsorption.However,
thekidney functionwas normal in all thepatients and the
elevated uric acid level cannot be explained by diuretic
therapy.
We conclude that although the number of patients
studiedwas small, we have a strong correlation between
hyperuricemia and mortality and between hyperurice-
mia and the NYHA class.We suggest that uric acid level
could be a prognostic factor in pulmonary hypertension
and peharps a guide to therapy. Further studies are
needed to evaluate the e¡ect of prostacycline or
endothelin receptor blockade therapy on uric acid level.
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